Israeli computerized light box developer SmartLight this month got the go-ahead from the Food and Drug Administration for expanded labeling for its products. On June 14, the FDA cleared SmartLight’s claim that, compared with conventional
Israeli computerized light box developer SmartLight this month got the go-ahead from the Food and Drug Administration for expanded labeling for its products. On June 14, the FDA cleared SmartLights claim that, compared with conventional light boxes, the companys motorized system substantially improves clinicians ability to see more detail in films. SmartLight submitted a study of more than 1000 radiologists reading quality control mammography films to back up its 510(k) filing (SCAN 5/26/99).
The FDA also cleared SmartLights claim that its viewing systems can reduce effects of age on the ability of older radiologists to see small, low-contrast objects. According to SmartLight, radiologists aged 45 to 60 viewing x-rays on its light boxes can detect smaller, lower-contrast objects than their 30-year-old colleagues can using conventional light boxes.
© 1999 Miller Freeman, Inc.All rights reserved.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.